Belgium - Re-Imbursed Pharmaceutical Market
Since 2014, Belgium Re-Imbursed Pharmaceutical Market jumped by 0.9points year on year. At 13.9 Percent of Generics in Value in 2019, the country was ranked number 15 comparing other countries in Re-Imbursed Pharmaceutical Market. Belgium is overtaken by Ireland, which was number 14 with 15.5 Percent of Generics in Value and is followed by Italy with 9.4 Percent of Generics in Value. Austria ranked the highest with 52.2 Percent of Generics in Value in 2019, that is +2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia recorded the worst performance at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 13.90 |
| 2018 | 13.30 |
| 2017 | 13.50 |
| 2016 | 14.10 |
| 2015 | 13.70 |
How does Belgium rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
| 14 |
#14
Ireland
|
15.50 % | 2019 | +4.0 % | -1.1 % | View data | |
| 15 |
#15
Belgium
|
13.90 % | 2019 | +4.5 % | +0.9 % | View data | |
| 16 |
#16
Italy
|
9.40 % | 2019 | +1.1 % | +1.6 % | View data | |